2019 IPO

NGM Biopharmaceuticals Stock

NGM Biopharmaceuticals is a drug discovery company developing biotherapeutics for the gastrointestinal endocrine system.

Sign up today and learn more about NGM Biopharmaceuticals Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About NGM Biopharmaceuticals Stock

NGM Biopharmaceuticals, Inc. is a privately held drug discovery company committed to identifying transformational medicines that dramatically improve human health. Based on emerging human clinical and genetic observations, the Company has devised several innovative experimental approaches to discover new therapies for the treatment of metabolic and cardiovascular diseases. Our current focus is on the gastrointestinal endocrine system, with an aim to identify novel factors implicated in the pathogenesis of type 2 diabetes and the apparent resolution of this grievous disease in patients who have undergone gastric bypass surgery.

Funding History

December 2009$26.6M
November 2011$55.4M
July 2013$50.0M
March 2015$106M
March 2015$57.5M


Vice President, Research

Hui Tian

Vice President, Business Development

Aetna Wun Trombley

Vice President, Clinical Research

Alex DePaoli

Chief Executive Officer

David Woodhouse

Executive Director, Research Operations

Marc Learned


William J. Rieflin

Vice President CMC and Technical Operations

Chuck Olson

Senior Director, Protein Sciences

Thomas Parsons


Luis Bayol

Founder, President and Chief Scientific Officer

Jin-Long Chen


EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: